Minocycline is Alzheimer’s Disease Efficacy
Now closed to new participants.
MADE is a phase II clinical trial to test efficacy and tolerability of 400mg and 200mg minocycline in disease modification of Alzheimer's disease (AD).
Minocycline is a well-used tetracycline antibiotic currently licensed for bacterial infections such as urinary tract infections, skin infections and acne. There is a substantial body of evidence to indicate that minocycline may be neuroprotective in neurodegenerative diseases such as AD.
For those who consent to take part, participants will be randomised to 24 months of daily treatment with 400mg Minocylcine, 200mg Mincocycline or matched placebo. They will undergo assessments with a Clinical Research Coordinator to measure their cognition and functioning. Participants will be closely followed-up during this time.
This study closed to new participants in March 2015.
Clinical Trials Gateway Link (click here)